Here is Dr. Javitt touting it on linkedin: "Here's the first peer-reviewed publication on #ZYESAMI. Another 93rd birthday tribute for Sami Said. This was a patient who developed clear respiratory failure from #covid?19, requiring 30 liters of nasal oxygen. Download the hi-res image and look at the "cotton-candy" appearance in the lung, especially on the right. After 24 hours of treatment, as shown in the paper, the lung is clear, the patient is down to 2 liters of oxygen, and is no longer in respiratory distress. This type of rapid recovery is not usually seen in COVID.
Of course, the plural of anecdote is not data. The motto at FDA is "in God we trust. Everybody else should please bring data." It's easy to report a case -- or multiple cases -- of dramatic improvement. Proving that such improvement is more common in drug-treated patients than in those given placebo and doing so across different hospitals, care teams, and patient populations in the middle of a pandemic is a different level of challenge."
The global pneumonia therapeutics market size was estimated at USD 11.9 billion in 2016 and is anticipated to grow at a CAGR of 8.0% throughout the forecast period. Increasing incidence of pneumococcal disease is a high impact rendering driver. Over the years, there has been a significant upsurge in number of community-acquired and ventilator-associated bacterial pneumonia. According to World Health Organization, the annual incidence is approximately 150.7 million cases, of which 7% to 13% require intensive treatment.
News 
Market Data 
Discover 
AI
